Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.

Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, Helfgott R, Marth C, Öhler L, Hubalek M, Lang A, Tinchon C, Haslbauer F, Redl A, Hock K, Hennebelle M, Mraz B, Gnant M.

Breast. 2020 Jan 31;50:64-70. doi: 10.1016/j.breast.2020.01.035. [Epub ahead of print]

2.

Complementation of the Mycoplasma synoviae MS-H vaccine strain with wild-type oppF1 influences its growth characteristics.

Kordafshari S, Marenda MS, Agnew R, Shil P, Shahid MA, Marth C, Konsak BM, Noormohammadi AH.

Avian Pathol. 2020 Feb 14:1-29. doi: 10.1080/03079457.2020.1729957. [Epub ahead of print]

PMID:
32054292
3.

The miR-34 family and its clinical significance in ovarian cancer.

Welponer H, Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Marth C, Hackl H, Fiegl H, Zeimet AG.

J Cancer. 2020 Jan 13;11(6):1446-1456. doi: 10.7150/jca.33831. eCollection 2020.

4.

Perception of Labial Size and Objective Measurements-Is There a Correlation? A Cross-Sectional Study in a Cohort Not Seeking Labiaplasty.

Widschwendter A, Riedl D, Freidhager K, Abdel Azim S, Jerabek-Klestil S, D'Costa E, Fessler S, Ciresa-König A, Marth C, Böttcher B.

J Sex Med. 2020 Jan 6. pii: S1743-6095(19)31826-0. doi: 10.1016/j.jsxm.2019.11.272. [Epub ahead of print]

PMID:
31918983
5.

High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.

Wolf D, Fiegl H, Zeimet AG, Wieser V, Marth C, Sprung S, Sopper S, Hartmann G, Reimer D, Boesch M.

Int J Cancer. 2020 Apr 1;146(7):2007-2018. doi: 10.1002/ijc.32818. Epub 2019 Dec 19.

PMID:
31800094
6.

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.

Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N.

Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019.

7.

Hopes and failures in front-line ovarian cancer therapy.

Tsibulak I, Zeimet AG, Marth C.

Crit Rev Oncol Hematol. 2019 Nov;143:14-19. doi: 10.1016/j.critrevonc.2019.08.002. Epub 2019 Aug 14. Review.

8.

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation Inc.

Gynecol Oncol. 2019 Aug;154(2):255-258. doi: 10.1016/j.ygyno.2019.04.677. No abstract available.

PMID:
31331494
9.

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation, Inc.

Int J Gynecol Cancer. 2019 Sep;29(7):1094-1097. doi: 10.1136/ijgc-2019-000441. Epub 2019 Jul 18. No abstract available.

PMID:
31320391
10.

Recurrence of genitals warts in pre-HPV vaccine era after laser treatment.

Widschwendter A, Böttcher B, Riedl D, Coban S, Mutz-Dehbalaie I, Matteucci Gothe R, Ciresa-König A, Marth C, Fessler S.

Arch Gynecol Obstet. 2019 Sep;300(3):661-668. doi: 10.1007/s00404-019-05242-5. Epub 2019 Jul 8.

11.

Clinical Impact of RANK Signalling in Ovarian Cancer.

Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG.

Cancers (Basel). 2019 Jun 8;11(6). pii: E791. doi: 10.3390/cancers11060791.

12.

Ovarian Cancer Stem Cell Heterogeneity.

Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet AG.

Adv Exp Med Biol. 2019;1139:201-221. doi: 10.1007/978-3-030-14366-4_12. Review.

PMID:
31134503
13.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.

Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

PMID:
31076365
14.

Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology.

Bjelic-Radisic V, Singer C, Tamussino K, Kölbl H, Petru E, Volgger B, Polterauer S, Oppelt P, Sevelda P, Bogner G, Marth C; Austrian Gynecologic Oncology Working Group.

Wien Klin Wochenschr. 2019 May;131(9-10):233-236. doi: 10.1007/s00508-019-1468-7. Epub 2019 Mar 18.

PMID:
30887224
15.

NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer.

Degasper C, Brunner A, Sampson N, Tsibulak I, Wieser V, Welponer H, Marth C, Fiegl H, Zeimet AG.

Tumour Biol. 2019 Feb;41(2):1010428319830002. doi: 10.1177/1010428319830002.

PMID:
30813866
16.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A.

N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.

PMID:
30811909
17.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

PMID:
30795951
18.

Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.

Wieser V, Tsibulak I, Degasper C, Welponer H, Leitner K, Parson W, Zeimet AG, Marth C, Fiegl H.

Cancer Sci. 2019 Mar;110(3):1117-1126. doi: 10.1111/cas.13955. Epub 2019 Feb 16.

19.

Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory.

Reich O, Braune G, Eppel W, Fiedler T, Graf A, Hefler L, Joura E, Kölbl H, Marth C, Pokieser W, Regitnig P, Reinthaller A, Tamussino K, Widschwendter A, Zeimet A, Kohlberger P.

Geburtshilfe Frauenheilkd. 2018 Dec;78(12):1232-1244. doi: 10.1055/a-0764-4875. Epub 2018 Dec 14.

20.

Immunotherapy in ovarian cancer: fake news or the real deal?

Marth C, Wieser V, Tsibulak I, Zeimet AG.

Int J Gynecol Cancer. 2019 Jan;29(1):201-211. doi: 10.1136/ijgc-2018-000011. Review.

PMID:
30640705
21.

Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects.

Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K.

Int J Gynecol Cancer. 2019 Jan;29(1):181-187. doi: 10.1136/ijgc-2018-000021.

PMID:
30640702
22.

Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.

Marth C.

Expert Rev Anticancer Ther. 2018 Oct;18(sup1):19-22. doi: 10.1080/14737140.2018.1513793.

PMID:
30223697
23.

A Copper-Mediated Conjugate Addition Approach to Analogues of Aconitine-Type Diterpenoid Alkaloids.

Doering NA, Kou KGM, Norseeda K, Lee JC, Marth CJ, Gallego GM, Sarpong R.

J Org Chem. 2018 Oct 19;83(20):12911-12920. doi: 10.1021/acs.joc.8b01967. Epub 2018 Sep 28.

24.

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.

Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.

Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.

25.

Evaluation of Vav3.1 as prognostic marker in endometrial cancer.

Boesch M, Sopper S, Marth C, Fiegl H, Wiedemair A, Rössler J, Hatina J, Wolf D, Reimer D, Zeimet AG.

J Cancer Res Clin Oncol. 2018 Oct;144(10):2067-2076. doi: 10.1007/s00432-018-2725-2. Epub 2018 Aug 6.

26.

Treatment of Retained Fetal Membranes in the Mare-A Practitioner Survey.

Warnakulasooriya DN, Marth CD, McLeod JA, Hanlon DW, Krekeler N.

Front Vet Sci. 2018 Jun 19;5:128. doi: 10.3389/fvets.2018.00128. eCollection 2018.

27.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv262. doi: 10.1093/annonc/mdy160. No abstract available.

PMID:
29741577
28.

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.

Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C.

Oncotarget. 2018 Apr 3;9(25):17501-17511. doi: 10.18632/oncotarget.24770. eCollection 2018 Apr 3.

29.
30.

The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.

Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2018 Apr;297(4):837-846. doi: 10.1007/s00404-018-4673-0. Epub 2018 Jan 22. Review. Erratum in: Arch Gynecol Obstet. 2018 Feb 14;:.

PMID:
29356953
31.

Front-line therapy of advanced epithelial ovarian cancer: standard treatment.

Marth C, Reimer D, Zeimet AG.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii36-viii39. doi: 10.1093/annonc/mdx450. Review.

32.

Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.

Reimer D, Boesch M, Wolf D, Marth C, Sopper S, Hatina J, Altevogt P, Parson W, Hackl H, Zeimet AG.

Int J Cancer. 2018 Apr 15;142(8):1640-1651. doi: 10.1002/ijc.31186. Epub 2017 Dec 14.

33.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
34.

Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.

Jahn B, Arvandi M, Rochau U, Fiegl H, Goebel G, Marth C, Siebert U.

J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.

PMID:
29091014
35.

Front-line therapy of advanced epithelial ovarian cancer: standard treatment.

Marth C, Reimer D, Zeimet AG.

Ann Oncol. 2017 Nov;28 Suppl 8:viii36-viii39. doi: 10.1093/annonc/mdx450.

PMID:
31952656
36.

Platinum or nonplatinum in recurrent ovarian cancer: that is the question.

Poveda A, Marth C.

Future Oncol. 2017 Oct;13(23s):11-16. doi: 10.2217/fon-2017-0317. Epub 2017 Oct 11. Review.

PMID:
29020823
37.

Managing relapsed ovarian cancer in a rapidly evolving landscape.

Poveda A, Marth C.

Future Oncol. 2017 Oct;13(23s):1. doi: 10.2217/fon-2017-0315. Epub 2017 Oct 11. No abstract available.

PMID:
29020820
38.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83. doi: 10.1093/annonc/mdx220. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv262.

39.

A Unifying Synthesis Approach to the C18-, C19-, and C20-Diterpenoid Alkaloids.

Kou KGM, Kulyk S, Marth CJ, Lee JC, Doering NA, Li BX, Gallego GM, Lebold TP, Sarpong R.

J Am Chem Soc. 2017 Oct 4;139(39):13882-13896. doi: 10.1021/jacs.7b07706. Epub 2017 Sep 20.

40.

European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, duBois A.

Int J Gynecol Cancer. 2017 Sep;27(7):1534-1542. doi: 10.1097/IGC.0000000000001041.

PMID:
30814245
41.

Innate immune genes in persistent mating-induced endometritis in horses.

Marth CD, Firestone SM, Hanlon D, Glenton LY, Browning GF, Young ND, Krekeler N.

Reprod Fertil Dev. 2018 Mar;30(3):533-545. doi: 10.1071/RD17157.

PMID:
28834688
42.

AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS).

Zeimet AG, Mori H, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer C, Wimmer K, Zschocke J, Marth C.

Arch Gynecol Obstet. 2017 Jul;296(1):123-127. doi: 10.1007/s00404-017-4392-y. Epub 2017 May 16.

43.

Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria.

Oberaigner W, Geiger-Gritsch S, Edlinger M, Daniaux M, Knapp R, Hubalek M, Siebert U, Marth C, Buchberger W.

Breast. 2017 Jun;33:178-182. doi: 10.1016/j.breast.2017.04.002. Epub 2017 Apr 15.

PMID:
28419909
44.

L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.

Abdel Azim S, Sprung S, Mutz-Dehbalaie I, Fessler S, Zeimet AG, Marth C.

Int J Gynecol Pathol. 2017 Jul;36(4):356-363. doi: 10.1097/PGP.0000000000000338.

PMID:
28221216
45.

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.

McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010.

46.

Incidental (Prophylactic) Salpingectomy at Benign Gynecologic Surgery and Cesarean Section: a Survey of Practice in Austria.

Potz FL, Tomasch G, Polterauer S, Laky R, Marth C, Tamussino K.

Geburtshilfe Frauenheilkd. 2016 Dec;76(12):1325-1329. doi: 10.1055/s-0042-116493.

47.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA.

Eur J Cancer. 2017 Jan;70:111-121. doi: 10.1016/j.ejca.2016.09.004. Epub 2016 Dec 1.

PMID:
27914241
48.

Oestrous cycle-dependent equine uterine immune response to induced infectious endometritis.

Marth CD, Firestone SM, Glenton LY, Browning GF, Young ND, Krekeler N.

Vet Res. 2016 Nov 8;47(1):110.

49.

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.

Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N.

Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4. Review.

PMID:
27821315
50.

Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.

Colombo N, Hardy-Bessard AC, Ferrandina G, Marth C, Romero I.

Expert Rev Anticancer Ther. 2016 Nov;16(sup1):11-19. Review.

PMID:
27797622

Supplemental Content

Support Center